NASDAQ:TPST Tempest Therapeutics (TPST) News Today $1.53 -0.09 (-5.56%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$1.53▼$1.6950-Day Range$1.36▼$3.7652-Week Range$1.06▼$4.21Volume59,901 shsAverage Volume161,031 shsMarket Capitalization$17.73 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address TPST Media Mentions By Week TPST Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TPST News Sentiment▼0.150.78▲Average Medical News Sentiment TPST News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TPST Articles This Week▼51▲TPST Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTempest to Present at the Jefferies Global Healthcare Conferencefinance.yahoo.com - May 31 at 8:26 PMAnalyst Ratings for Tempest Therapeuticsmarkets.businessinsider.com - May 30 at 7:42 PMTempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancersfinance.yahoo.com - May 25 at 7:44 PMTempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancersfinance.yahoo.com - May 25 at 7:44 PMTempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - May 19 at 5:59 PMTempest Therapeutics, Inc. Forecasted to Earn Q2 2023 Earnings of ($0.64) Per Share (NASDAQ:TPST)americanbankingnews.com - May 17 at 1:36 AMTempest Therapeutics, Inc. to Post Q2 2023 Earnings of ($0.52) Per Share, William Blair Forecasts (NASDAQ:TPST)americanbankingnews.com - May 16 at 1:28 AMHC Wainwright & Co. Reiterates Tempest Therapeutics (TPST) Buy Recommendationmsn.com - May 12 at 10:20 AMTempest Therapeutics: Tempest Reports First Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - May 11 at 2:58 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Tempest Therapeutics (TPST), MannKind (MNKD) and Alkermes (ALKS)markets.businessinsider.com - May 11 at 9:57 AMTempest Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 10 at 6:48 PMTempest Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 10 at 6:48 PMTempest Therapeutics, Inc. (TPST) Upgraded to Buy: What Does It Mean for the Stock?msn.com - May 1 at 2:38 PMTempest Therapeutics (NASDAQ:TPST) Price Target Raised to $14.00americanbankingnews.com - May 1 at 1:52 AM8-K: Tempest Therapeutics, Inc.marketwatch.com - April 29 at 10:37 AMLadenburg Thalmann Maintains Tempest Therapeutics (TPST) Buy Recommendationmsn.com - April 29 at 10:37 AMShort Interest in Tempest Therapeutics, Inc. (NASDAQ:TPST) Declines By 29.9%americanbankingnews.com - April 29 at 8:08 AMTempest Announces Positive Results From Phase 1b/2 Trial Of TPST-1120 In Hepatocellular Cancermarkets.businessinsider.com - April 28 at 1:52 PMTempest Soars after Positive Clinical Data for TPST-1120msn.com - April 28 at 1:52 PMTempest surges ~40% as TPST-1120 shows promise in liver cancer trialmsn.com - April 28 at 1:52 PMTempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinomafinance.yahoo.com - April 28 at 8:51 AMTempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinomafinance.yahoo.com - April 27 at 6:51 PMTempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meetingbenzinga.com - April 26 at 8:02 PMTempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meetingfinance.yahoo.com - April 26 at 8:02 PMTempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meetingfinance.yahoo.com - April 17 at 10:07 AMTempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Updateamericanbankingnews.com - March 31 at 7:26 AMTempest Therapeutics Stock (NASDAQ:TPST), Dividendsbenzinga.com - March 30 at 2:09 PMTempest Therapeutics, Inc. Forecasted to Earn Q2 2023 Earnings of ($0.71) Per Share (NASDAQ:TPST)americanbankingnews.com - March 28 at 1:38 AMTempest Therapeutics (NASDAQ:TPST) Given New $6.00 Price Target at Piper Sandleramericanbankingnews.com - March 26 at 4:24 AMShakespeare’s The Tempest plot summarybbc.co.uk - March 24 at 9:53 AMEquities Analysts Offer Predictions for Tempest Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:TPST)americanbankingnews.com - March 24 at 6:18 AMHC Wainwright Reiterates Buy Rating for Tempest Therapeutics (NASDAQ:TPST)americanbankingnews.com - March 24 at 5:32 AMTempest Therapeutics: Tempest Reports Year End 2022 Financial Results and Provides Business Updatefinanznachrichten.de - March 23 at 7:28 AMTempest Reports Year End 2022 Financial Results and Provides Business Updatefinance.yahoo.com - March 22 at 10:36 PMTempest Reports Year End 2022 Financial Results and Provides Business Updatefinance.yahoo.com - March 22 at 5:35 PMTempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meetingfinance.yahoo.com - March 15 at 6:44 PMTempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meetingfinance.yahoo.com - March 15 at 6:44 PMTempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meetingfinance.yahoo.com - March 14 at 9:36 PMKS2 Music: The Tempestbbc.co.uk - February 18 at 6:07 PMBears are Losing Control Over Tempest Therapeutics, Inc. (TPST), Here's Why It's a 'Buy' Nowfinance.yahoo.com - December 5 at 6:34 PMTempest to Present at the Piper Sandler 34th Annual Healthcare Conferencefinance.yahoo.com - November 22 at 6:24 PMTempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancerfinance.yahoo.com - November 10 at 3:47 PMTempest Reports Third Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - November 8 at 8:56 AMTempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meetingfinance.yahoo.com - November 2 at 1:11 PM6KMPH, DDI : Benzinga's Top Ratings Upgrades, Downgrades For...msn.com - September 15 at 11:34 AMTempest to Present at the H.C. Wainwright 24th Annual Global Investment Conferencefinance.yahoo.com - September 7 at 10:10 AMTempest to Present at the H.C. Wainwright 24th Annual Global Investment Conferencefinance.yahoo.com - September 7 at 10:10 AMTempest Therapeutics GAAP EPS of -$0.79seekingalpha.com - August 17 at 8:21 PMTempest Therapeutics, Inc. Tops Q2 EPS by 13cinvesting.com - August 17 at 12:19 AMTempest Reports Second Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - August 15 at 8:22 AM Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMMX News COCP News VYNE News MTCR News CPIX News ANGN News ONTX News ACST News EQ News TFFP News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:TPST) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.